Motley Fool Wealth Management LLC Has $6.43 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Motley Fool Wealth Management LLC decreased its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 8.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 153,835 shares of the biopharmaceutical company's stock after selling 14,180 shares during the quarter. Motley Fool Wealth Management LLC owned 0.17% of Ultragenyx Pharmaceutical worth $6,425,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Algert Global LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 46.9% in the 3rd quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company's stock worth $4,105,000 after acquiring an additional 23,580 shares during the last quarter. Bamco Inc. NY purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth about $2,666,000. Principal Financial Group Inc. raised its holdings in Ultragenyx Pharmaceutical by 740.0% during the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company's stock worth $4,802,000 after buying an additional 76,150 shares during the period. Cerity Partners LLC purchased a new stake in Ultragenyx Pharmaceutical during the third quarter valued at about $1,773,000. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after buying an additional 294 shares during the period. Institutional investors own 97.67% of the company's stock.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, insider John Richard Pinion sold 14,439 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $607,881.90. Following the completion of the transaction, the insider now directly owns 107,766 shares in the company, valued at $4,536,948.60. This represents a 11.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Howard Horn sold 1,785 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total transaction of $72,114.00. Following the completion of the sale, the chief financial officer now directly owns 106,169 shares of the company's stock, valued at approximately $4,289,227.60. This trade represents a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 136,370 shares of company stock worth $5,751,499. Company insiders own 5.80% of the company's stock.

Remove Ads

Ultragenyx Pharmaceutical Stock Down 2.8 %

Shares of NASDAQ:RARE traded down $1.07 during trading on Friday, reaching $37.82. The stock had a trading volume of 323,194 shares, compared to its average volume of 791,720. The stock has a fifty day simple moving average of $41.64 and a two-hundred day simple moving average of $46.84. The firm has a market capitalization of $3.50 billion, a price-to-earnings ratio of -5.97 and a beta of 0.67. Ultragenyx Pharmaceutical Inc. has a 52 week low of $36.71 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. On average, analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on RARE. Wedbush reaffirmed a "neutral" rating and issued a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Wells Fargo & Company upped their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research report on Friday, December 20th. HC Wainwright reaffirmed a "buy" rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Cantor Fitzgerald restated an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research note on Thursday. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $92.79.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.